Elutia Inc. (ELUT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Elutia Inc. (ELUT) Healthcare & Pipeline Overview

Elutia Inc. focuses on developing and commercializing advanced drug-eluting biologics, targeting critical areas in neurostimulation, wound care, and breast reconstruction, thereby positioning itself as a key player in the evolving biotechnology landscape.

What Is the Investment Thesis for ELUT?

Elutia Inc. presents a compelling investment thesis driven by several key value drivers. The company boasts a profit margin of 282.6%, significantly above industry averages, indicating strong operational efficiency. With a P/E ratio of 0.9, Elutia is currently undervalued compared to its peers, suggesting potential for price appreciation as market conditions improve. Growth catalysts include the increasing demand for advanced wound care solutions, particularly in the context of an aging population and rising chronic disease prevalence. The global wound care market is projected to reach $20 billion by 2027, providing a substantial growth opportunity for Elutia's product lines. Additionally, the company’s ongoing development of innovative products, such as CanGarooRM and SimpliDerm, positions it well within the competitive landscape of biotechnology. However, potential risks include regulatory challenges and market competition, which could impact growth trajectories. Overall, Elutia's unique product offerings and market positioning provide a solid foundation for future growth.

Based on FMP financials and quantitative analysis

ELUT Key Highlights

Market Cap of $39.9M reflects early-stage growth potential in the biotechnology sector.

• Profit margin of 282.6% indicates exceptional operational efficiency and product demand.
• P/E ratio of 0.9 suggests the company is undervalued relative to its earnings.
• Gross margin of 49.1% showcases strong pricing power and cost management.
• Beta of 0.71 indicates lower volatility compared to the broader market, appealing to risk-averse investors.

Who Are ELUT's Competitors?

ELUT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ELUT's Key Strengths?

High profit margin indicating strong operational efficiency.

• Innovative product offerings addressing critical healthcare needs.
• Established market presence with a growing customer base.

What Are ELUT's Weaknesses?

Limited brand recognition compared to larger competitors.

• Dependence on a narrow product line for revenue generation.
• Relatively small scale of operations with only 51 employees.

What Could Drive ELUT Stock Higher?

FDA approval for CanGarooRM expected in Q3 2026, which could significantly enhance market access.

• Expansion of sales force to increase market penetration and customer outreach.
• Development of new product lines targeting additional surgical applications.

What Are the Key Risks for ELUT?

Financial-distress signal — its Altman Z-Score of -6.51 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Regulatory hurdles that could delay product launches.
• Competition from larger, established biotechnology firms with greater resources.
• Market adoption challenges for new products in a competitive landscape.

What Are the Growth Opportunities for ELUT?

• Expansion into New Therapeutic Areas: Elutia Inc. plans to expand its product offerings into new therapeutic areas, particularly in regenerative medicine. By leveraging its existing technology platforms, Elutia can develop innovative solutions that address unmet medical needs, enhancing its market share and revenue potential.
• Geographic Market Expansion: Elutia is exploring opportunities to expand its presence in international markets, particularly in Europe and Asia, where demand for advanced medical technologies is rising. The European wound care market alone is projected to grow at a CAGR of 5.6% from 2023 to 2028. By establishing partnerships with local distributors and healthcare providers, Elutia can tap into these lucrative markets and diversify its revenue streams.
• Product Line Diversification: The company is actively working on diversifying its product portfolio to include additional drug-eluting biologics that cater to various surgical specialties. This strategy aligns with the growing trend towards personalized medicine and targeted therapies. The global market for drug-eluting devices is expected to reach $30 billion by 2026, providing Elutia with significant growth opportunities as it introduces new products tailored to specific patient needs.
• Strategic Collaborations: Elutia Inc. is pursuing strategic collaborations with research institutions and other biotechnology firms to enhance its R&D capabilities. Collaborations can accelerate product development timelines and reduce costs associated with clinical trials. The biotechnology sector is increasingly leaning towards partnerships to drive innovation, and Elutia's proactive approach can position it favorably in a competitive environment.
• Regulatory Approvals: The company is focused on obtaining regulatory approvals for its existing and pipeline products, which can significantly enhance its market access and credibility. Successful FDA approvals for innovative products can lead to rapid commercialization and increased sales. The regulatory landscape in the U.S. is evolving, with a growing emphasis on expedited pathways for breakthrough technologies, which Elutia can leverage to its advantage.

What Threats Does ELUT Face?

• Intense competition from established medical technology firms.
• Regulatory challenges that could delay product approvals.
• Market volatility impacting funding and investment in biotechnology.

What Are ELUT's Competitive Advantages?

• Strong intellectual property portfolio protecting innovative product designs.
• Established relationships with healthcare providers and institutions enhance market access.
• Unique product offerings that address specific medical needs differentiate Elutia from competitors.

What Does ELUT Do?

Elutia Inc., incorporated in 2015 and headquartered in Silver Spring, Maryland, is a commercial-stage biotechnology company dedicated to the development and commercialization of drug-eluting biologics products. The company operates across three primary segments: Device Protection, Women's Health, and Cardiovascular, showcasing a diverse portfolio aimed at improving patient care. Notably, Elutia's flagship product, the CanGaroo Envelope, is designed to accommodate cardiac implantable electronic devices such as pacemakers and internal defibrillators, enhancing device longevity and patient safety. Additionally, the company has innovated the CanGarooRM, which combines the CanGaroo envelope with antibiotics to mitigate infection risks post-surgery. Elutia also offers ProxiCor for cardiac tissue repair and pericardial closure, Tyke for neonatal cardiac structure repair, and VasCure for peripheral vasculature reconstruction. In the Women's Health segment, SimpliDerm utilizes human acellular dermal matrices for tissue repair and reconstruction in various surgical applications, including breast reconstruction following mastectomy. Elutia serves hospitals and healthcare facilities through a robust sales force, independent agents, and distributors, ensuring broad market reach. The company was formerly known as Aziyo Biologics, Inc. and rebranded to Elutia Inc. in September 2023, reflecting its commitment to innovation and growth in the healthcare sector.

What Products and Services Does ELUT Offer?

• Develops drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction.
• Offers the CanGaroo Envelope for cardiac implantable electronic devices.
• Creates CanGarooRM, combining the CanGaroo envelope with antibiotics to reduce infection risks.
• Provides ProxiCor for cardiac tissue repair and pericardial closure.
• Develops Tyke for neonatal cardiac structure repair.
• Offers VasCure for peripheral vasculature reconstruction.
• Utilizes SimpliDerm for tissue repair and reconstruction in various surgical applications.

How Does ELUT Make Money?

• Generates revenue through the sale of biologics products to hospitals and healthcare facilities.
• Utilizes a direct sales force, independent sales agents, and distributors to reach customers.
• Focuses on innovative product development to meet the needs of healthcare providers and patients.
• Engages in strategic partnerships to enhance product offerings and market reach.

What Industry Does ELUT Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in medical technology and increasing healthcare demands. The global biotechnology market is projected to reach $2.44 trillion by 2028, with significant contributions from sectors such as drug development, medical devices, and biologics. Elutia Inc. is well-positioned within this landscape, particularly in the niche of drug-eluting biologics, which are gaining traction due to their enhanced efficacy and safety profiles. The competitive landscape includes established players as well as emerging companies, making innovation and regulatory compliance critical for success. Elutia's focus on specialized applications in neurostimulation and wound care allows it to carve out a unique market position amidst growing competition.

Who Are ELUT's Key Customers?

• Hospitals and healthcare facilities in the U.S.
• Surgeons and medical professionals specializing in cardiac and reconstructive surgery.
• Healthcare providers seeking advanced wound care solutions.

Company Profile

Elutia Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Gaithersburg, US. The company is led by CEO C. Randal Mills. ELUT has traded publicly since 2020.

Return on assets is 90.3%, showing how much profit it generates from its asset base. ELUT trades at a trailing price-to-earnings ratio of 0.90, below the Healthcare sector average of ~23x. A current ratio of 2.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 118.3%, the inverse of the P/E and a quick read on earnings relative to price.

ELUT Valuation & Market Position

With a $39.9M market cap, Elutia Inc. sits in the micro-cap segment of the market. Relative to its peer group, ELUT's quantitative score of 23/100 is below the peer average of 78/100.

Quarterly Financial Performance: Elutia Inc.

Revenue for Elutia Inc. came in at $2.4M during Q2 2026, a 22.1% contraction versus the preceding quarter. The company recorded a net loss of $7.6M, with diluted EPS of $-0.17. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, ELUT averaged $0.24 in diluted EPS.

Elutia Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -6.51 places it in the distress zone, a signal of elevated financial risk.

Elutia Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 3.7% above estimates on average.

Wall Street analysts project Elutia Inc. revenue of about $7.5M for fiscal 2026, with EPS near $-0.63.

ELUT Financials

ELUT Latest News

ELUT Analyst Consensus

ELUT MoonshotScore

Latest Elutia Inc. Analysis

ELUT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources